{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:27Z","timestamp":1740126147857,"version":"3.37.3"},"reference-count":3,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1111\/bjd.16052","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T22:12:39Z","timestamp":1507673559000},"page":"571-571","source":"Crossref","is-referenced-by-count":7,"title":["The optimal regimen of brentuximab vedotin for CD30<sup>+<\/sup>\n cutaneous lymphoma: are we there yet?"],"prefix":"10.1093","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-1057","authenticated-orcid":false,"given":"S.","family":"Geller","sequence":"first","affiliation":[{"name":"Dermatology Service; Department of Medicine; Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine; New York NY U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.L.","family":"Myskowski","sequence":"additional","affiliation":[{"name":"Dermatology Service; Department of Medicine; Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine; New York NY U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Stanford University School of Medicine; Stanford CA U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Lymphoma Service; Department of Medicine; Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine; New York NY U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Lymphoma Service; Department of Medicine; Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine; New York NY U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,18]]},"reference":[{"key":"10.1111\/bjd.16052-BIB0001|bjd16052-cit-0001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1111\/bjd.16052-BIB0002|bjd16052-cit-0002","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.16052-BIB0003|bjd16052-cit-0003","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/bjd.15801","article-title":"Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature","volume":"177","author":"Stranzenbach","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16052\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:30:15Z","timestamp":1676367015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/2\/571\/6732237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,18]]},"references-count":3,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16052","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"type":"print","value":"0007-0963"}],"subject":[],"published":{"date-parts":[[2017,12,18]]}}}